Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks hschlauch! Would love to hear your though on this and the multigene poster when it arrives when you have the time. Cheers!
Full data PR should be out anytime after 12:45pm ET today.
Thanks greens. I didn’t know p1 was done way back and in younger patients. I’m confident this will be a $10+ stock, but maybe on nash readout. Maybe they moved hip to December to make the two readouts closer for a cushion in a worst case scenario for hip. But I’m hoping they will pass. GLTA!
Wainwright analyst says ONCS could apply for BTD based on current p2b data
https://www.smarteranalyst.com/2017/11/10/heres-bull-sees-next-oncosec-medical-inc-oncs-back-phase-ii-combination-trial-success/
Wainwright analyst says ONCS could apply for BTD based on current p2b data
https://www.smarteranalyst.com/2017/11/10/heres-bull-sees-next-oncosec-medical-inc-oncs-back-phase-ii-combination-trial-success/
https://www.prnewswire.com/news-releases/oncosec-announces-positive-updated-long-term-follow-up-data-from-phase-2-trial-of-immunopulse-il-12-in-combination-with-pembrolizumab-demonstrating-a-progression-free-survival-rate-pfs-of-57-at-15-months-in-predicted-anti-pd-1-300551642.html
Detailed data to be presented at SITC at 12:45pm ET. Should see a PR this afternoon.
MRNS's pop today was due to SAGE reporting positive phase 3 PPD data as MRNS is also in the space and has its phase 2 PPD data due next quarter.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=136064841
OncoSec Announces Preclinical Data Demonstrating Multi-Gene Expression Platform for Delivery of Multiple Cancer Immunotherapies at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017
- OncoSec's Polycistronic Interleukin-12 Immune Modulator (PIIM) DNA Plasmid Vector Enables Simultaneous Delivery of Multiple Complementary Anti-Cancer Agents
- OncoSec Presents Emerging Preclinical Data Demonstrating its Novel Platform at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
https://finance.yahoo.com/news/oncosec-announces-preclinical-data-demonstrating-130000800.html
Weren’t the majority of ONCS p2b patients biomarker-predicted non-responders, although a good fraction were indeed actual anti-PD1 failures?
OncoSec Medical Appoints Daniel J. O'Connor as CEO to Lead Next Stage of Growth as a Fully Integrated Late Stage Development and Commercial Company
https://www.prnewswire.com/news-releases/oncosec-appoints-daniel-j-oconnor-as-chief-executive-officer-to-lead-next-stage-of-growth-as-a-fully-integrated-late-stage-development-and-commercial-company-300551401.html
(Reposting for sticky)
MRNS +35%/PM on the news (eom)
SAGE (+68%/PM) Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression
- Statistically significant mean reduction in the HAM-D score compared to placebo at 60 hours demonstrated in both trials
- Brexanolone provided a rapid and durable reduction over 30 days in depressive symptoms as measured by HAM-D in both placebo-controlled multi-center trials
- Positive results support planned regulatory submissions; Company to host conference call today at 8:00 A.M. ET
http://www.businesswire.com/news/home/20171109005296/en/Sage-Therapeutics-Announces-Brexanolone-Achieves-Primary-Endpoints
If they hadn’t already done a few rounds of capital raising in the last two months, yes. But you need to catch up on the facts.
You mean $2.20s?
OncoSec shares turn hot as microcap reports promising PhII data for an I/O one-two punch
https://endpts.com/oncosec-shares-turn-hot-as-microcap-reports-promising-phii-data-for-an-io-one-two-punch/
More fun will arrive once the 13G’s start flowing in. Hopefully there are some big names in them.
Also this was true of today’s patients. See contrast with registration trial patients and why they could easily meet endpoints.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135994905
In their previous updates they noted tumor reduction in non-treated areas as well. That is likely their basis for the claim.
As for next data, they’ve said interim data from the lead registration trial will be available mid 2018, based on which they will apply for AA if BORR is 30%+. The program is on Fast Track so AA eligible.
Could you please elaborate? Thanks.
You still think this is a crap company?
$ONCS CR rate=38% $INCY CR rate=14%
— avidresearch (@avidresearch) November 8, 2017
ONCS +84%
Adam F compares this company to $23B INCY saying it has better data in today’s stat news article.
Same here:
$ONCS CR rate=38% $INCY CR rate=14%
— avidresearch (@avidresearch) November 8, 2017
Me neither but someone told me he compares us to INCY (a multi B co) and also mentions Cohen investment.
OncoSec Announces Positive Updated Long-Term Follow-Up Data from Phase 2 Trial of ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Progression Free Survival Rate (PFS) of 57% at 15 months in Predicted Anti-PD-1 Non-Responder Melanoma Patients
https://www.prnewswire.com/news-releases/oncosec-announces-positive-updated-long-term-follow-up-data-from-phase-2-trial-of-immunopulse-il-12-in-combination-with-pembrolizumab-demonstrating-a-progression-free-survival-rate-pfs-of-57-at-15-months-in-predicted-anti-pd-1-300551642.html
Will tiny OncoSec break out with promising melanoma immunotherapy study results?
https://www.statnews.com/2017/11/08/oncosec-melanoma-immunotherapy/
Will tiny $ONCS break out with promising melanoma immunotherapy study results? https://t.co/L0I2NmuFyv $INCY #SITC2017
— Adam Feuerstein ✡️ (@adamfeuerstein) November 8, 2017
I suppose if they wanted to, he did not have to make this move to ONCS. Was just curious. Anyway I’m wondering if Steve Cohen had anything to do with this change after his recent position in the company.
Are you hinting at the possibility of a reverse merger between the two companies?
ONCS appoints fmr. ADXS CEO as new CEO
https://ir.oncosec.com/press-releases/detail/1924
That is correct. ONCS does/will not owe any royalties to Inovio.
Not to add fuel to the speculation but don’t forget the potential value in the multigene pipeline as well.
The odds are always stacked against small companies like ONCS. The best we can do is do our due diligence and make a bet with $ we are comfortable losing. GLTA.
Bitcoin a new asset class, not a crypto-currency: CME's Melamed
https://www.reuters.com/article/us-cme-group-bitcoin/bitcoin-a-new-asset-class-not-a-crypto-currency-cmes-melamed-idUSKBN1D712M
Takeda taps Portal Instruments in needle-free drug delivery deal worth up to $100M
https://www.fiercebiotech.com/medtech/takeda-taps-portal-instruments-needle-free-drug-delivery-deal-worth-up-to-100m
Takeda Pharmaceutical and Portal Instruments are partnering to develop the latter's needle-free drug delivery device for potential use with the former's biologic medicines. Portal stands to earn up to $100 million in milestone payments and royalties.
The pair will initially focus on Entyvio, Takeda's drug for ulcerative colitis and Crohn's disease that is currently administered via intravenous infusion. The drugmaker is already seeking a new way to deliver it, and a subcutaneous formulation of the drug is in phase 3 trial, according to a statement.
Portal's device is reusable; a patient loads it with a cartridge that is prefilled with a drug and self-administers the dose, said Portal CEO Patrick Anquetil. It works by pressurizing the liquid drug into a jet that, when it contacts the skin, pierces it and delivers the drug to the target area. It was developed in the lab of Ian Hunter at MIT.
What sets the device apart is that it is computer-controlled. Anquetil likens the software to cruise control in a car—just as cruise control maintains a car's speed regardless of terrain, the Portal device always delivers the same amount of a biologic, taking into consideration factors such as a change in the drug's viscosity due to temperature.
In February this popped to $1.90+ on a neutral article from Adam. He has said he will reassess the data after SITC. A more than neutral feedback from him would be nice.
Picked up another 2k at $1.24 today. Hope all is well Wait!
What the royal purge means for Saudi Arabia — and its oil
https://www.washingtonpost.com/amphtml/business/economy/what-the-royal-purge-means-for-saudi-arabia--and-its-oil/2017/11/06/9cba9142-c256-11e7-afe9-4f60b5a6c4a0_story.html
“Unprecedented” Pentagon health committee could undermine FDA
https://www.politico.com/story/2017/11/06/defense-department-health-committee-fda-drugs-military-244604
The Defense Department — and not FDA — would have the power to approve drugs and medical devices under the defense policy bill that’s being hammered out by a conference committee, alarming congressional staff and Health and Human Services officials who say it would undermine medical safety and potentially put soldiers at risk.
Section 732 of the Senate’s version of the National Defense Authorization Act creates a new regulatory structure that would allow the Pentagon to sign off on unapproved devices and drugs for emergency use on military personnel and others in harm’s way. The bill is in conference committee with final language expected as early as this week.
If they have unblinded data and are participating in this event, I would assume they met endpoints.
Viking Therapeutics to Participate in Ligand Pharmaceuticals Analyst Day, November 14 in New York City
https://investor.ligand.com/press-releases/detail/340/reminder-ligand-to-host-analyst-day-on-november-14th-in